spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Sense Accelerates Instrument-Free Molecular Diagnostic Test for COVID-19

Phillips-Medisize

Pioneering new class of diagnostic product will transform fight against pandemic Scale-up with Phillips-Medisize underway to ensure timely delivery and distribution

April 1, 2020 – Sense Biodetection Limited (Sense) has today announced an accelerated programme to launch the world’s first instrument-free, point-of-care molecular diagnostic test for SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic.

Sense is partnering closely with Phillips-Medisize, a Molex company and leading global medical device innovator, developer and manufacturer, to scale-up production of its test in order to meet the growing demand for rapid diagnostics.

Sense’s VerosTM SARS-CoV-2 is a simple disposable test that uses a nasal swab sample to give an ultra-rapid result without the need for any instrumentation. As a molecular test its performance is equivalent to Gold Standard laboratory tests but it is easy to use in any setting and results are available in under 10 minutes. The test is fully self-contained and can be widely distributed to wherever it is needed, overcoming the logistical and contamination problems associated with machine-based testing.

Harry Lamble, chief executive officer at Sense, commented:

“Our VerosTM COVID-19 test product can allow infected patients to be isolated sooner whilst providing reassurance to uninfected individuals including healthcare workers that they can return to work without infecting others. Due to its flexibility, speed and accuracy, the test can be deployed for rapid patient triage within hospitals as well as primary care practices, pharmacies and community centres and even distributed for use by individuals in isolation who suspect they may have COVID-19.”

Sense’s VerosTM SARS-CoV-2 exploits proprietary chemistry and device technologies developed by Sense over the last six years for other infectious disease applications including influenza (flu). In 2019, the company announced a £12.3m Series A investment round co-led by Cambridge Innovation Capital (CIC) and Earlybird. It has since rapidly scaled its operations and is in a strong position to impact the current pandemic. The COVID-19 product will be one of the first tests to be marketed by the company under its VerosTM brand.

Mike Anstey, investment partner at CIC, commented:

“Sense is developing a product that will be hugely important to the global effort to contain COVID-19 in the coming months and potentially years. CIC and co-investors Earlybird, Mercia, and Jonathan Milner are working closely with Sense to ensure it has all the resources it needs as it accelerates towards launch of the first disposable nucleic acid test for COVID-19.”

About Sense: Sense Biodetection Limited is a molecular diagnostics company focused on bringing tests to the True Point-of-CareTM. Sense was founded in 2014 by Harry Lamble and Ralph Lamble, who combined their respective expertise in molecular sciences and medical device design to realise their vision of empowering patients through decentralised testing. Sense has developed a new class of diagnostic product to break down the barriers that have led to the current model of centralised testing. Sense products are simple, ultra-rapid, handheld tests which remove the need for advanced hardware to determine a result. Sense operates from bespoke laboratory, development and manufacturing facilities in Cambridge and Oxford, UK and is growing rapidly as it takes its first products to market.


Contact for media enquiries: info@sense-bio.com
phone +31 252 576 888
email eu_sales@phillipsmedisize.com
web www.phillipsmedisize.com
email Edisonstraat 1 Hillegom 2181 AB
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Business Continuity Plan - Message from Protagen Protein Services (PPS)

Following the recent COVID-19 outbreak, we at Protagen Protein Services (PPS) are preparing for all eventualities. Please be assured that PPS will continue to operate as normal providing you with all of the professional support and service you have to come to expect from us. Given the gravity of the situation, and to protect our staff, clients, and communities from the spread of the virus, we have taken various measures within a scope of a Business Continuity Plan:
More info >>


White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

Industry Events

INTERPHEX 2020

15-17 July 2020, Javits Center NYC


More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement